Covetrus FCF Margin
Delisted
The Free Cash Flow Margin of Covetrus (CVET) as of Jul 26, 2026 is 0.92 %. In the previous year, Free Cash Flow Margin was -0.12 % — a change of -896.67% (higher).
Get this data via API
Financial Data API
FCF Margin
0.92 %
YoY
-896.67%
Last updated:
Free Cash Flow Margin of Covetrus is 2026 0.92 % . Free Cash Flow Margin of Covetrus was 2025 -0.12 % . It decreases by -896.67% higher compared to the previous year.
Access this data via the Eulerpool API
Covetrus Stock analysis
What does Covetrus do? Covetrus Inc is a global company specializing in providing services and products for veterinarians, animal clinics, and pet owners. It was formed in 2019 through a merger between the animal health divisions of Henry Schein and Vets First Choice. Covetrus traces its history back to 1856 when Henry Schein was founded as a small wholesale drug company. Over the years, the company expanded into new industries and markets. In the 2000s, Henry Schein began serving the animal health industry and established Vets First Choice in 2010 to offer a wider range of services and products to veterinarians and animal clinics. With the merger of Vets First Choice and Henry Schein's animal health division in 2019, Covetrus was created as a company with a broad spectrum of products and services for the animal health industry. Covetrus is headquartered in Portland, Maine, USA, and operates in over 25 countries. Its business model is based on providing services and products for veterinarians, animal clinics, and pet owners. The company is divided into several business segments, including diagnostics, pharmaceuticals, and consumables. In the diagnostics area, Covetrus offers a wide range of laboratory diagnostic services for veterinarians, including blood tests, imaging, fecal tests, and genetic tests. These test results help veterinarians diagnose and treat diseases in pets. In the pharmaceutical area, Covetrus offers veterinary medicines for various types of pets, including dogs, cats, and horses. These medicines are developed by leading pharmaceutical companies, and Covetrus provides veterinarians with a reliable supply chain for these products. The most recent business segment of Covetrus is the consumables area. Here, the company offers a wide range of products for veterinarians and animal clinics, including medical devices, surgical instruments, consumables for routine examinations, and more. In addition to these three main business segments, Covetrus also offers a variety of services, including practice management systems, training for veterinarians and animal clinics, financial services, and more. These services are designed to help veterinarians and animal clinics optimize their operations and improve their quality. The company has also developed a mobile application called 'Covetrus Connect' which provides veterinarians and animal clinics with an easier way to access products and services, place orders, and manage their operations. Overall, Covetrus is an innovative and rapidly growing company in the animal health industry. With a wide range of products and services tailored to the needs of veterinarians, animal clinics, and pet owners, the company is well-positioned to continue growing in this emerging market. Covetrus is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Covetrus stock
Free Cash Flow Margin of Covetrus is 0.92 % in 2026.
Access this data via the Eulerpool API
Margins — Covetrus
All Key Metrics — Covetrus
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth